

Head Office

Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory

Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

20 May 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai 400 051

Scrip Code: 524669

Symbol: HESTERBIO

Dear Sir/ Madam:

Subject: Outcome of Board Meeting

This is with reference to our letter dated 12 May 2022 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Audited Financial Results for the quarter and year ended 31 March 2022 and to consider declaration of dividend, if any, on the equity shares of the Company, for the financial year 2021-22.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the followings:

- 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2022, as recommended by Audit Committee and the Audited Standalone and Consolidated Financial Statements for the year ended 31 March 2022.

Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended time to time), we hereby state that the Statutory Auditors of the Company, Chadulal M. Shah & Co., Chartered Accountants (FRN: 101698W) have issued an Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31 March 2022.

- 2) Recommended dividend of 100% that is INR 10 per equity share of INR 10 each for the financial year 2021-22, subject to approval of members in the ensuing Annual General Meeting.

We attach herewith:

- 1) The approved standalone and consolidated audited financial results and auditors reports.
- 2) Press Release issued in this regard

We would be publishing the extract of results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11:30 a.m. (IST) and concluded at 12:30 a.m. (IST)



HESTER

Hester Biosciences Limited

Head Office

Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory

Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in

Toll Free 1800 233 7937


www.hester.in

CIN L99999GJ1987PLC022333

We shall inform you in due course the date on which the Company will hold its Annual General Meeting for the year ended 31 March 2022 and the date from which dividend, if approved by the shareholders, will be paid or warrants thereof dispatched to the shareholders.

You are requested to take the above information on your record.

Sincerely
For Hester Biosciences Limited



Vinod Mali
Company Secretary &
Compliance Officer

Enclosure: As above

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2022

Amount in INR Million

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|---|------------------------|------------------|------------------------|-----------------|-----------------|
| | | 31 March 2022 | 31 December 2021 | 31 March 2021 | 31 March 2022 | 31 March 2021 |
| | | Audited (Refer note 6) | Unaudited | Audited (Refer note 6) | Audited | Audited |
| | Income | | | | | |
| 1 | Revenue from Operations | 502.51 | 540.01 | 631.58 | 2,193.51 | 2,084.77 |
| 2 | Other Income | 10.81 | 12.22 | 1.20 | 46.57 | 16.48 |
| 3 | Total income | 513.32 | 552.23 | 632.78 | 2,240.08 | 2,101.25 |
| 4 | Expenses | | | | | |
| | (a) Cost of material consumed | 83.65 | 77.64 | 91.32 | 349.31 | 241.75 |
| | (b) Purchases of stock-in-trade | 124.74 | 113.93 | 80.31 | 392.97 | 252.09 |
| | (c) Change in inventories of finished goods, traded goods and work in progress | (49.39) | (50.31) | 27.50 | (125.26) | 40.14 |
| | (d) Employee benefits expense | 96.96 | 96.70 | 97.87 | 391.19 | 334.51 |
| | (e) Finance cost | 13.83 | 3.65 | 4.72 | 24.68 | 39.47 |
| | (f) Depreciation and amortisation expense | 25.48 | 23.34 | 24.46 | 95.02 | 96.33 |
| | (g) Other expenses | 146.01 | 149.74 | 128.42 | 579.61 | 496.35 |
| | Total expenses | 441.28 | 414.69 | 454.60 | 1,707.52 | 1,500.64 |
| 5 | Profit before tax and exceptional items | 72.04 | 137.54 | 178.18 | 532.56 | 600.61 |
| 6 | Exceptional items (refer note 2) | - | - | (52.78) | - | (52.78) |
| 7 | Profit before tax | 72.04 | 137.54 | 125.40 | 532.56 | 547.83 |
| 8 | Tax Expense | | | | | |
| | Current tax | 19.64 | 35.33 | 49.78 | 142.53 | 163.65 |
| | Deferred tax | 2.92 | (3.37) | (12.97) | (5.14) | (14.83) |
| | Total tax expense | 22.56 | 31.96 | 36.81 | 137.39 | 148.82 |
| 9 | Profit after tax | 49.48 | 105.58 | 88.59 | 395.17 | 399.01 |
| 10 | Other Comprehensive Income | | | | | |
| | Items that will not be reclassified to Profit or Loss | | | | | |
| | Remeasurement Gain/(Loss) on Defined Benefit Plans | 1.22 | (1.10) | 0.01 | (2.10) | 2.86 |
| | Income tax impact | (0.31) | 0.28 | - | 0.53 | (0.72) |
| | Total Other Comprehensive Income | 0.91 | (0.82) | 0.01 | (1.57) | 2.14 |
| 11 | Total Comprehensive Income for the period / year | 50.39 | 104.76 | 88.60 | 393.60 | 401.15 |
| 12 | Paid-up equity share capital | | | | 85.07 | 85.07 |
| 13 | Other Equity | | | | 2,599.27 | 2,290.74 |
| 14 | Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR) | 5.82 | 12.41 | 10.41 | 46.45 | 46.90 |

STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS AT 31 MARCH 2022

Amount in INR Million

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|---|------------------------|------------------------|
| I. ASSETS | | |
| (1) Non-current assets | | |
| (a) Property Plant & Equipment | 839.50 | 863.07 |
| (b) Capital Work-in-Progress | 802.24 | 32.88 |
| (c) Other Intangible Assets | 3.59 | 3.30 |
| (d) Intangible Assets under Development | 16.85 | 4.31 |
| (e) Biological Assets other than the Bearer Plants | - | 0.56 |
| (f) Financial Assets | | |
| (i) Investments | 646.89 | 438.85 |
| (ii) Loans | - | 7.40 |
| (iii) Other Financial Assets | 60.41 | 41.14 |
| (g) Other Non-current Assets | 210.22 | 32.58 |
| Total Non-current Assets | 2,579.70 | 1,424.09 |
| (2) Current assets | | |
| (a) Inventories | 707.34 | 570.12 |
| (b) Financial Assets | | |
| (i) Trade Receivables | 569.16 | 455.50 |
| (ii) Cash and Cash Equivalents | 15.28 | 12.44 |
| (iii) Bank Balances other than (ii) above | 4.53 | - |
| (iv) Loans | 58.76 | 56.99 |
| (v) Other Financial Assets | 146.64 | 127.17 |
| (c) Other Current Assets | 163.01 | 173.84 |
| Total Current Assets | 1,664.72 | 1,396.06 |
| Total Assets | 4,244.42 | 2,820.15 |
| II. EQUITY AND LIABILITIES | | |
| (1) Equity | | |
| (a) Share capital | 85.07 | 85.07 |
| (b) Other equity | 2,599.27 | 2,290.74 |
| | 2,684.34 | 2,375.81 |
| (2) Liabilities | | |
| Non-current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 732.49 | 26.76 |
| (ii) Other Financial Liabilities | 5.53 | 3.03 |
| (b) Non Current Provision | 10.77 | - |
| (c) Deferred Tax Liabilities (Net) | 62.92 | 68.06 |
| Total Non-current Liabilities | 811.71 | 97.85 |
| Current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 486.64 | 132.25 |
| (ii) Trade Payables | | |
| -Total outstanding dues of micro enterprises and small enterprises | 19.88 | 2.98 |
| -Total outstanding dues of creditors other than micro enterprises and small enterprises | 90.39 | 137.27 |
| (iii) Other Financial Liabilities | 125.88 | 9.07 |
| (b) Other Current Liabilities | 13.81 | 26.83 |
| (c) Provisions | 2.39 | 8.67 |
| (d) Current Tax Liabilities | 9.38 | 29.42 |
| Total Current Liabilities | 748.37 | 346.49 |
| Total Liabilities | 1,560.08 | 444.34 |
| Total Equity and Liabilities | 4,244.42 | 2,820.15 |

STATEMENT OF AUDITED STANDALONE CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2022

Amount in INR Million

| Particulars | Year Ended | |
|--|-------------------|-----------------|
| | 31 March 2022 | 31 March 2021 |
| | Audited | Audited |
| A. Cash Flow from Operating Activities | | |
| Profit Before Tax | 532.56 | 547.83 |
| Adjustments For: | | |
| Depreciation and Amortisation Expense | 95.02 | 96.33 |
| Exceptional Items | - | 52.78 |
| Provision for doubtful debt | 2.28 | 2.87 |
| Bad Debts Written off | 19.86 | 6.90 |
| (Profit) / Loss on Sale of Property, Plant & Equipment | (0.69) | 2.69 |
| Profit on buy-back of shares by subsidiary | (2.26) | - |
| Interest expense | 13.94 | 37.15 |
| Unrealised foreign exchange loss / (gain) | 7.85 | - |
| Interest Income | (19.02) | (2.62) |
| Operating profit before working capital changes | 649.54 | 743.93 |
| Adjustments For: | | |
| Trade Receivables | (138.36) | (17.65) |
| Inventories | (137.21) | 34.20 |
| Other Assets | 10.83 | (50.77) |
| Trade Payables | (29.98) | 4.17 |
| Other Current Liabilities | (13.02) | 2.94 |
| Short-term Provisions | 4.49 | 4.25 |
| Loans | (1.77) | (56.03) |
| Other Financial Liability | 2.69 | 0.44 |
| Other Financial Assets | (23.79) | (119.56) |
| Cash Generated From Operations | 323.42 | 545.92 |
| Income tax paid (net) | (164.37) | (134.89) |
| Net cash generated from operating activities (A) | 159.05 | 411.03 |
| B. Cash flow from investing activities | | |
| Capital expenditure on Property, Plant and Equipment, including capital advances and capital work-in-progress and on intangible assets | (906.69) | (42.50) |
| Proceeds from Sale of Property, Plant and Equipment | 1.79 | 0.42 |
| Payment towards investment in subsidiaries | - | (8.25) |
| Payment towards investment in joint venture entity | (208.15) | - |
| Proceeds from buy-back of shares by subsidiary | 9.79 | - |
| Interest received | 2.63 | 2.35 |
| Bank / margin money deposits withdrawn / (Investment) (Net) | (5.20) | 10.74 |
| Net cash used in investing activities (B) | (1,105.83) | (37.24) |
| C. Cash flow from financing activities | | |
| Proceeds from long term borrowings | 861.42 | - |
| Repayment of long term borrowings | (128.95) | (19.04) |
| Proceeds/(Repayment) of Short-term Borrowings (net) | 315.78 | (300.91) |
| Interest Paid | (13.56) | (37.15) |
| Dividend Paid | (85.07) | (56.15) |
| Net cash generated from /(used in) financing activities (C) | 949.62 | (413.25) |
| Net decrease in cash and cash equivalents (A)+(B)+(C) | 2.84 | (39.46) |
| Cash and cash equivalents at the beginning of the period | 12.44 | 51.90 |
| Cash and cash equivalents at the end of the period | 15.28 | 12.44 |

Notes:

- 1 The standalone financial results of Hester Biosciences Limited (the "Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 20 May 2022.
- 2 Exceptional items during the quarter and year ended 31 March 2021 includes Loss on disposal of Patan Farm aggregating to INR 33.21 million and impairment of interest accrued/ loan to subsidiary aggregating to INR 19.57 million.
- 3 Following are the details of segment wise revenue, results, segment assets and liabilities:

Amount in INR Million

| Particulars | Quarter Ended | | | Year Ended | |
|---|-----------------|------------------|-----------------|-----------------|-----------------|
| | 31 March 2022 | 31 December 2021 | 31 March 2021 | 31 March 2022 | 31 March 2021 |
| Segment Revenue | | | | | |
| a. Poultry Healthcare | 400.94 | 416.50 | 485.49 | 1,712.31 | 1,558.58 |
| b. Animal Healthcare | 101.57 | 123.51 | 146.09 | 481.20 | 526.19 |
| Total Revenue from Operations | 502.51 | 540.01 | 631.58 | 2,193.51 | 2,084.77 |
| Segment Results | | | | | |
| a. Poultry Healthcare | 83.73 | 134.25 | 120.54 | 537.88 | 388.39 |
| b. Animal Healthcare | (9.95) | (1.10) | 27.84 | (16.81) | 201.89 |
| Total Segment Results | 73.78 | 133.15 | 148.38 | 521.07 | 590.28 |
| Segment Results | | | | | |
| a. Finance Costs | 13.83 | 3.65 | 4.72 | 24.68 | 39.47 |
| b. Other unallocable expenditure/(income) (Net) | (12.09) | (8.04) | 18.26 | (36.17) | 2.98 |
| Profit before Tax | 72.04 | 137.54 | 125.40 | 532.56 | 547.83 |
| Segment Assets | | | | | |
| a. Poultry Healthcare | 2,362.17 | 2,204.74 | 1,822.52 | 2,362.17 | 1,822.52 |
| b. Animal Healthcare | 310.29 | 328.68 | 325.89 | 310.29 | 325.89 |
| Unallocated Assets | 1,571.96 | 988.11 | 671.74 | 1,571.96 | 671.74 |
| Total | 4,244.42 | 3,521.53 | 2,820.15 | 4,244.42 | 2,820.15 |
| Segment Liabilities | | | | | |
| a. Poultry Healthcare | 151.37 | 146.45 | 143.64 | 151.37 | 143.64 |
| b. Animal Healthcare | 46.12 | 43.74 | 39.59 | 46.12 | 39.59 |
| Unallocated Liabilities | 1,362.59 | 697.39 | 261.11 | 1,362.59 | 261.11 |
| Total | 1,560.08 | 887.58 | 444.34 | 1,560.08 | 444.34 |

- 4 During the quarter, the Company has acquired 50% equity shares in the joint venture entity, Thrishool Exim Limited, Tanzania with an investment aggregating to INR 208.15 million.
- 5 The Board of Directors has recommended a dividend of INR 10 per equity share (100%) for FY22, subject to the approval of the shareholders in the ensuing Annual General Meeting.
- 6 The figures for the last quarters are the balancing figures between the audited figures in respect of the full year ending 31 March 2022 and 31 March 2021 and the unaudited published year-to-date figures upto 31 December 2021 and 31 December 2020 respectively, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

For and on behalf of the Board of Directors



Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Ahmedabad
Date: 20 May 2022

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2022

Amount in INR Million

| Sr. No. | | Quarter Ended | | | Year Ended | |
|---------|---|------------------------|------------------|------------------------|-----------------|-----------------|
| | | 31 March 2022 | 31 December 2021 | 31 March 2021 | 31 March 2022 | 31 March 2021 |
| | | Audited (refer note 6) | Unaudited | Audited (Refer note 6) | Audited | Audited |
| | Income | | | | | |
| 1 | Revenue from Operations | 564.69 | 556.89 | 641.75 | 2,350.06 | 2,143.32 |
| 2 | Other Income | 71.92 | 27.77 | 24.76 | 137.41 | 46.84 |
| 3 | Total Income | 636.61 | 584.66 | 666.51 | 2,487.47 | 2,190.16 |
| 4 | Expenses | | | | | |
| | (a) Cost of Materials Consumed | 164.06 | 146.06 | 142.47 | 606.53 | 386.59 |
| | (b) Purchase of Stock-in-Trade | 33.01 | 44.39 | 22.39 | 126.18 | 79.67 |
| | (c) Change in inventories of finished goods, traded goods and work in progress | (43.10) | (57.38) | 11.69 | (105.56) | 35.97 |
| | (d) Employee Benefit Expense | 122.67 | 106.60 | 111.45 | 453.32 | 389.23 |
| | (e) Finance Cost | 15.00 | 9.62 | 14.35 | 40.64 | 66.04 |
| | (f) Depreciation and Amortisation Expense | 51.31 | 51.70 | 36.30 | 165.81 | 133.14 |
| | (g) Other Expenses | 184.80 | 166.91 | 155.98 | 669.76 | 565.28 |
| | Total Expenses | 527.75 | 467.90 | 494.63 | 1,956.68 | 1,655.92 |
| 5 | Profit before Share of Profit of Joint Venture entity, Exceptional Items and Tax | 108.86 | 116.76 | 171.88 | 530.79 | 534.24 |
| | Share of Profit in Joint Venture entity | 4.23 | - | - | 4.23 | - |
| 6 | Profit before Exceptional Items and Tax | 113.09 | 116.76 | 171.88 | 535.02 | 534.24 |
| 7 | Exceptional Items (Refer Note 2) | - | - | (33.21) | - | (33.21) |
| | Profit before tax | 113.09 | 116.76 | 138.67 | 535.02 | 501.03 |
| 8 | Tax Expense | | | | | |
| | Current tax | 21.21 | 36.57 | 51.86 | 147.84 | 169.47 |
| | Deferred tax | 1.81 | (3.11) | (14.17) | (7.66) | (15.42) |
| | Total Tax Expense | 23.02 | 33.46 | 37.69 | 140.18 | 154.05 |
| 9 | Net Profit for the period / year | 90.07 | 83.30 | 100.98 | 394.84 | 346.98 |
| 10 | Other Comprehensive Income | | | | | |
| | Items that will not be reclassified to Profit or Loss | | | | | |
| | Remeasurement Gain/(Loss) on Defined Benefit Plans | 1.22 | (1.10) | 0.01 | (2.10) | 2.86 |
| | Income Tax Impact | (0.31) | 0.28 | (0.00) | 0.53 | (0.72) |
| | Items that will be reclassified to Profit or Loss | | | | | |
| | Foreign Currency Translation Reserve | 5.94 | (1.15) | (17.59) | 9.78 | (17.94) |
| | Income Tax Impact | - | - | - | - | - |
| | Total Other Comprehensive Income | 6.85 | (1.97) | (17.58) | 8.21 | (15.80) |
| 11 | Total Comprehensive Income for the period / year | 96.92 | 81.33 | 83.40 | 403.05 | 331.18 |
| 12 | Profit for the period attributable to: | | | | | |
| | (i) Owners of the Company | 77.23 | 84.84 | 96.90 | 393.20 | 344.30 |
| | (ii) Non Controlling Interest | 12.84 | (1.54) | 4.08 | 1.64 | 2.68 |
| 13 | Other Comprehensive Income for the period attributable to: | | | | | |
| | (i) Owners of the Company | 6.85 | (1.97) | (3.50) | 8.21 | (15.80) |
| | (ii) Non Controlling Interest | - | - | (14.08) | - | - |
| 14 | Total Comprehensive Income for the period attributable to: | | | | | |
| | (i) Owners of the Company | 84.08 | 82.87 | 93.40 | 401.41 | 328.50 |
| | (ii) Non Controlling Interest | 12.84 | (1.54) | (10.00) | 1.64 | 2.68 |
| 15 | Paid-up equity share capital | | | | 85.07 | 85.07 |
| 16 | Other Equity | | | | 2,514.78 | 2,198.01 |
| 17 | Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR) | 10.59 | 9.79 | 11.87 | 46.41 | 40.79 |

STATEMENT OF AUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT 31 MARCH 2022

Amount in INR Million

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|--|------------------------|------------------------|
| I. ASSETS | | |
| (1) Non-current assets | | |
| (a) Property Plant & Equipment | 2,368.13 | 1,322.87 |
| (b) Capital Work-in-Progress | 802.24 | 1,087.37 |
| (c) Other Intangible Assets | 3.59 | 4.21 |
| (d) Intangible Assets under Development | 16.85 | 4.31 |
| (e) Biological Assets other than the Bearer Plants | - | 0.56 |
| (f) Financial Assets | | |
| (i) Investments | 212.38 | - |
| (ii) Other Financial Assets | 60.56 | 41.14 |
| (g) Other Non-current Assets | 210.23 | 34.98 |
| Total Non-current Assets | 3,673.98 | 2,495.44 |
| (2) Current assets | | |
| (a) Inventories | 753.82 | 622.22 |
| (b) Financial Assets | | |
| (i) Trade Receivables | 552.80 | 492.12 |
| (ii) Cash and Cash Equivalents | 247.50 | 212.69 |
| (iii) Bank Balances other than (ii) above | 4.53 | - |
| (iv) Loans | 60.80 | 56.99 |
| (v) Other Financial Assets | 150.10 | 127.31 |
| (c) Other Current Assets | 178.08 | 103.72 |
| Total Current Assets | 1,947.63 | 1,615.05 |
| Total Assets | 5,621.61 | 4,110.49 |
| II. EQUITY AND LIABILITIES | | |
| (1) Equity | | |
| (a) Share capital | 85.07 | 85.07 |
| (b) Other equity | 2,514.78 | 2,198.01 |
| Equity Attributable to Owners | 2,599.85 | 2,283.08 |
| Non Controlling Interest | 74.09 | 76.50 |
| Total Equity | 2,673.93 | 2,359.58 |
| (2) Liabilities | | |
| Non-current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 1,645.44 | 828.42 |
| (ii) Lease Liabilities | 52.70 | 51.84 |
| (iii) Other Financial Liabilities | 5.66 | 3.03 |
| (b) Non Current Provision | 12.72 | - |
| (c) Deferred Tax Liabilities (Net) | 65.10 | 72.76 |
| (d) Other non-current liabilities | 197.08 | 181.20 |
| Total Non-current Liabilities | 1,978.70 | 1,137.25 |
| Current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 580.27 | 216.73 |
| (ii) Lease Liabilities | 3.27 | 3.17 |
| (iii) Trade Payables | 180.19 | 280.86 |
| (iv) Other Financial Liabilities | 141.54 | 11.76 |
| (b) Other Current Liabilities | 51.51 | 26.36 |
| (c) Provisions | 2.82 | 43.95 |
| (d) Current Tax Liabilities | 9.38 | 30.83 |
| Total Current Liabilities | 968.98 | 613.66 |
| Total Liabilities | 2,947.68 | 1,750.91 |
| Total Equity and Liabilities | 5,621.61 | 4,110.49 |

STATEMENT OF AUDITED CONSOLIDATED CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2022

Amount in INR Million

| Particulars | YEAR ENDED | |
|--|-------------------|-----------------|
| | 31 March 2022 | 31 March 2021 |
| | Audited | Audited |
| A. Cash Flow from Operating Activities | | |
| Profit Before Tax | 535.02 | 501.03 |
| Adjustments For: | | |
| Depreciation and Amortisation Expense | 165.81 | 133.14 |
| Share of Profit in Joint Venture Entity | (4.23) | - |
| Exceptional Items | - | 33.21 |
| Provision for doubtful debt | 4.71 | 2.87 |
| Bad Debts Written off | 19.86 | 6.90 |
| (Profit) / Loss on Sale of Property, Plant & Equipment | (0.69) | 23.22 |
| Amortisation of deferred grant | (89.05) | (23.23) |
| Interest expense | 25.76 | 40.25 |
| Unrealised foreign exchange loss / (gain) | 7.85 | - |
| Interest Income | (19.03) | (12.94) |
| Operating profit before working capital changes | 646.01 | 704.44 |
| Adjustments For: | | |
| Trade Receivables | (87.79) | 82.47 |
| Inventories | (131.60) | 17.46 |
| Other Assets | (74.36) | 25.09 |
| Other Non Current Assets | 2.39 | 16.90 |
| Trade Payables | (100.67) | 80.63 |
| Other Liabilities | 25.15 | (85.65) |
| Provisions | 6.87 | (4.10) |
| Loans | (3.81) | (56.03) |
| Other Financial Liability | 4.37 | 63.98 |
| Other Financial Assets | (27.39) | (125.28) |
| Cash Generated From Operations | 259.17 | 719.89 |
| Income tax paid (net) | (171.09) | (139.36) |
| Net cash generated from / (used in) operating activities (A) | 88.08 | 580.53 |
| B. Cash flow from investing activities | | |
| Capital expenditure on Property, Plant and Equipment, including capital advances and capital work-in-progress and on intangible assets | (957.10) | (407.42) |
| Proceeds from Sale of Property, Plant and Equipment | 1.79 | 0.42 |
| Payment towards investment in joint venture entity | (208.15) | - |
| Interest received | 2.64 | 12.67 |
| Bank / margin money deposits withdrawn / (Investment) (Net) | (5.06) | 10.60 |
| Net cash generated from / (used in) investing activities (B) | (1,165.88) | (383.72) |
| C. Cash flow from financing activities | | |
| Proceeds from long term borrowings | 1,033.47 | 182.11 |
| Repayment of long term borrowings | (180.44) | (118.44) |
| Proceeds/(Repayment) of Short-term Borrowings (net) | 315.66 | (292.64) |
| Proceeds from Issue of Share Capital in subsidiary entities from Non-controlling | 3.98 | 19.64 |
| Payment to Non-controlling interest shareholders for buy-back of shares in | (8.03) | - |
| Interest Paid | (25.38) | (40.25) |
| Proceeds from Grants | 61.91 | 123.54 |
| Dividend Paid (Including Dividend Distribution Tax) | (85.07) | (56.15) |
| Net cash (used in) / generated from financing activities (C) | 1,116.10 | (182.19) |
| Exchange rate fluctuation arising on consolidation (D) | (3.49) | (37.24) |
| Net increase/ (decrease) in cash and cash equivalents (A) + (B) + (C) | 34.81 | (22.62) |
| Cash and cash equivalents at the beginning of the year | 212.69 | 235.31 |
| Cash and cash equivalents at the end of the year | 247.50 | 212.69 |

Notes:

- 1 The consolidated financial results of Hester Biosciences Limited (the "Company") and its subsidiaries (together referred as the "Group") and its joint venture entity have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 20 May 2022.
- 2 Exceptional items during the year ended 31 March 2021 includes loss on disposal of Patan farm aggregating to INR 33.21 million.
- 3 Following are the details of consolidated segment wise revenue, results, segment assets and liabilities:

Amount in INR Million

| Particulars | Quarter Ended | | | Year Ended | |
|--|-----------------|------------------|-----------------|-----------------|-----------------|
| | 31 March 2022 | 31 December 2021 | 31 March 2021 | 31 March 2022 | 31 March 2021 |
| Segment Revenue | | | | | |
| a. Poultry Healthcare | 396.80 | 419.17 | 527.00 | 1,718.31 | 1,564.51 |
| b. Animal Healthcare | 167.89 | 137.72 | 114.75 | 631.75 | 578.81 |
| Total Income from Operations (Net) | 564.69 | 556.89 | 641.75 | 2,350.06 | 2,143.32 |
| Segment Results | | | | | |
| a. Poultry Healthcare | 86.61 | 140.05 | 168.48 | 547.38 | 389.11 |
| b. Animal Healthcare | 27.88 | (4.06) | (12.51) | 9.06 | 180.92 |
| Total Segment Results | 114.49 | 135.99 | 155.97 | 556.44 | 570.03 |
| a. Finance Costs | 15.00 | 9.62 | 14.35 | 40.64 | 66.04 |
| b. Share of Profit in Joint Venture Entity | 4.23 | - | - | 4.23 | - |
| c. Other unallocable expenditure/ (income) (Net) | (9.37) | 9.61 | 2.95 | (14.99) | 2.96 |
| Profit before Tax | 113.09 | 116.76 | 138.67 | 535.02 | 501.03 |
| Segment Assets | | | | | |
| a. Poultry Healthcare | 2,360.77 | 2,278.72 | 1,891.35 | 2,360.77 | 1,891.35 |
| b. Animal Healthcare | 2,123.38 | 2,122.28 | 1,993.65 | 2,123.38 | 1,993.65 |
| Unallocated Assets | 1,137.46 | 549.37 | 225.49 | 1,137.46 | 225.49 |
| Total | 5,621.61 | 4,950.37 | 4,110.49 | 5,621.61 | 4,110.49 |
| Segment Liabilities | | | | | |
| a. Poultry Healthcare | 219.44 | 179.59 | 220.23 | 219.44 | 220.23 |
| b. Animal Healthcare | 343.50 | 446.84 | 309.87 | 343.50 | 309.87 |
| Unallocated Liabilities | 2,384.74 | 1,744.58 | 1,220.81 | 2,384.74 | 1,220.81 |
| Total | 2,947.68 | 2,371.01 | 1,750.91 | 2,947.68 | 1,750.91 |

- 4 During the quarter, the Company has acquired 50% equity shares in the joint venture entity, Thrishool Exim Limited, Tanzania with an investment aggregating to INR 208.15 million.
- 5 The Board of Directors has recommended a dividend of INR 10 per equity share (100%) for FY22, subject to the approval of the shareholders in the ensuing Annual General Meeting.
- 6 The figures for the last quarters are the balancing figures between the audited figures in respect of the full year ending 31 March 2022 and 31 March 2021 and the unaudited published year-to-date figures upto 31 December 2021 and 31 December 2020 respectively, being the date of the end of the third quarter of the respective financials years which were subjected to limited review.


- 7 Key numbers of the standalone financial results of the Company for the quarter and financial year ended 31 March 2022 are as under:

Amount in INR Million

| Particulars | Quarter Ended | | | Year Ended | |
|---|------------------|---------------------|------------------|------------------|------------------|
| | 31 March 2022 | 31 December 2021 | 31 March 2021 | 31 March 2022 | 31 March 2021 |
| Total Income | 513.32 | 552.23 | 632.78 | 2,240.08 | 2,101.25 |
| Profit Before Tax and Exceptional Items | 72.04 | 137.54 | 178.18 | 532.56 | 600.61 |
| Profit before tax | 72.04 | 137.54 | 125.40 | 532.56 | 547.83 |
| Profit After Tax | 49.48 | 105.58 | 88.59 | 395.17 | 399.01 |
| Total Comprehensive Income | 50.39 | 104.76 | 88.60 | 393.60 | 401.15 |

The Standalone Financial Results are available at the Company's website www.hester.in and on the website of the stock exchanges www.bseindia.com and www.nseindia.com.

For and on behalf of the Board of Direct



Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Ahmedabad
Date: 20 May 2022

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.

Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

Opinion

We have audited the accompanying standalone financial results of **Hester Biosciences Limited** ('the Company') for the quarter and year ended March 31, 2022, ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the Statement:


- is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of



the statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions; misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

1. The Statement includes the results for the quarter ended March 31, 2022, being the balancing figures between the audited figures with respect to full financial year ended March 31, 2022, and the published unaudited year-to-date figures upto the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.

For, Chandulal M. Shah & Co.

Chartered Accountants

FRN 101698W



Arpit D. Shah


Partner

M. No. 135188

UDIN: 22135188AJHCAT9954

Place: Ahmedabad

Date: May 20, 2022



Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's Report on Quarterly and Year to date Audited Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

Opinion

We have audited the accompanying statement of consolidated financial results of **Hester Biosciences Limited** ("the Holding company"), its subsidiaries and joint venture entity (the Holding, its subsidiaries and joint venture entity together referred to as "the Group") for the quarter and year ended March 31, 2022, ("the Statement"), attached herewith, being submitted by the Holding company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of report of other auditors on separate audited financial statements/financial information of subsidiaries and unaudited financial results as certified management of Joint Venture, the Statement:

- i. includes the results of the following subsidiaries & Joint Venture:

| Sr. No. | Name of the Company | Relationship |
|---------|--|----------------------|
| 1 | Texas Lifesciences Private Limited | Subsidiary |
| 2 | Hester Biosciences Nepal Private Limited | Subsidiary |
| 3 | Hester Biosciences Africa Limited | Subsidiary |
| 4 | Hester Biosciences Kenya Limited | Subsidiary |
| 5 | Hester Biosciences Tanzania Limited | Subsidiary |
| 6 | Thrishool Exim Limited | Joint Venture Entity |

- ii. is presented in accordance with the requirements of Regulation 33 of Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial results.

Management's Responsibilities for the Consolidated Financial Results

The Statement have been prepared on the basis of the consolidated financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net consolidated profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the Companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the Companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are also responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the Group of which we are the independent auditors to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matter

- a. The accompanying Statement includes the audited financial results other financial information, in respect of the 5 subsidiaries, whose financial statements reflect total assets of INR 2,010.04 million as at March 31, 2022 and total revenue of INR 218.47 million and INR 557.63 million, total net profit after tax of INR 30.15 million and INR 2.85 million and total comprehensive income of INR 30.08 million and INR 5.16 million for the quarter and the year ended on that date respectively, and net cash inflows of INR 31.98 million for the year ended March 31, 2022, as considered in the Statement which have been audited by their respective independent auditors.

The independent auditors' reports on the financial results of the above referred entities have been furnished to us by the Management and our opinion on the in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.



Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

- b. The accompanying Statement includes the group's share of Net Profit after tax of INR 4.23 million for the year ended on that date, in respect of 1 joint venture entity, whose unaudited financial results as certified by the management of this entity has been furnished to us by the management and our opinion on those consolidated financial statements in so far as it relates to the amounts and disclosures included in respect of this joint venture is based solely on such unaudited financial statements.

In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.

- c. Certain of these subsidiaries and joint venture entity are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries ('local GAAP'). The Holding Company's management has converted the financial results of such subsidiaries from local GAAP to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based on the conversion adjustments prepared by the management of the Holding company and reviewed by us.
- d. The consolidated annual financial results include the results for the quarter ended March 31, 2022, being the balancing figures between the audited figures with respect to full financial year ended March 31, 2022, and the published unaudited year-to-date figures upto the end of the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations.

For, Chandulal M. Shah & Co.

Chartered Accountants

FRN 101698W



Arpit D. Shah

Partner

M. No. 135188

UDIN: 22135188AJHCCB6636



Place: Ahmedabad

Date: May 20, 2022